DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
You are receiving this because you have an account on www.oneGRAVESvoice.com | ||
To unsubscribe from these emails, click here |
Trusted Resources: News & Meetings
Latest announcements and gatherings
Teprotumumab Improves Short and Long-Term Clinical Outcomes in Thyroid Eye Disease
Most adults with thyroid eye disease receiving an infusion of teprotumumab every 3 weeks for a 24-week period had a reduction of at least 2 mm in proptosis, with a long-term response observed in 67% of participants, according to study data.
“These analyses provide insight into both the short-term and long-term efficacy and safety of teprotumumab and are clinically relevant as all objective signs and symptoms of thyroid eye disease, especially proptosis and diplopia, which can be resistant to medical therapy, were markedly and significantly improved with teprotumumab,” George J. Kahaly, MD, PhD, a professor of medicine, endocrinology and metabolism at Johannes Gutenberg University Medical Center in Mainz, Germany, and colleagues wrote in a study published in The Lancet Diabetes & Endocrinology.


Related Content
-
Evidence & EducationPredictive Score for the Development or Progression of Graves’ Orbitopathy in Patients With Newly Diagnosed Gr...Objective: To construct a predictive sc...
-
Evidence & EducationConsensus Statement of the European Group on Graves’ Orbitopathy (EUGOGO) on Management of Graves’ Orbit...Graves’ orbitopathy (GO) constitutes a...
-
Evidence & EducationCommon Immunosuppressive Monotherapy for Graves’ Ophthalmopathy: A Meta-AnalysisBackground: Several immunosuppressive t...
-
Videos & VisualsDr. Alon Kahana – Management of Dry Eyeshttps://www.youtube.com/watch?v=xat5SBU_...
-
Community CenterAngels Announcer Victor Rojas Stays Strong for His Wife in Her Health BattleShe braces herself for the worst. Stayin...
-
Evidence & EducationRelation between Therapy Options for Graves’ Disease and the Course of Graves’ Ophthalmopathy: A Systema...Background: The relation between therap...
-
Evidence & EducationDoes Early Response to Intravenous Glucocorticoids Predict the Final Outcome in Patients With Moderate-To-Severe and...Purpose: Intravenous glucocorticoids (i...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.